Market Overview

Global Renal Cell Cancer (RCC) Disease Forecast and Market Analysis to 2035 - ResearchAndMarkets.com

Share:

The "Renal
Cell Cancer (RCC) Disease Forecast and Market Analysis to 2035"

report has been added to ResearchAndMarkets.com's
offering.

Renal cell cancer (RCC) is a tumor that originates in the renal cortex,
the outer part of the kidney between the renal capsule and the renal
medulla. Around 85% of all malignant kidney tumors are RCC, with other
types including transitional cell carcinoma of the renal pelvis and
Wilms' tumor (nephroblastoma). The incidence of RCC is higher in those
over the age of 60 years, suggesting that the aging population may play
a significant role in current and future disease burden. Overall, RCC
incidence rates have been steadily increasing in both men and women in
the US, Japan, and five major EU markets since the 1970s.

Market snapshot

  • The RCC market will experience moderate growth despite a number of
    patent expiries of key brands over the forecast period.
  • Sutent continues to be the most widely prescribed therapy in locally
    advanced and metastatic renal cell cancer.
  • Incident cases of renal cell carcinoma are expected to increase by
    more than a quarter during 2016-36.
  • Sutent is currently the standard of care for newly diagnosed RCC
    patients, with Afinitor the standard of care in the second-line
    setting.
  • Companies are increasingly developing pipeline drugs to use in
    combination with currently marketed therapies.

Key Topics Covered:

1 Forecast: Renal Cell Cancer

  • Executive Summary
  • Market Overview And Trends
  • Methodology And Market Definition
  • Afinitor (Everolimus)
  • Avastin (Bevacizumab)
  • Avelumab
  • Cabometyx (Cabozantinib)
  • Inlyta (Axitinib)
  • Keytruda (Pembrolizumab)
  • Lenvima (Lenvatinib)
  • Nexavar (Sorafenib)
  • Opdivo (Nivolumab)
  • Sutent (Sunitinib)
  • Tecentriq (Atezolizumab)
  • Torisel (Temsirolimus)
  • Votrient (Pazopanib)
  • Primary Research Methodology

2 Treatment: Renal Cell Cancer

  • Executive Summary
  • Primary Research Methodology
  • Disease Definition And Diagnosis
  • Patient Segmentation
  • Current Treatment Options
  • Prescribing Trends

3 Epidemiology: Renal Cell Carcinoma

  • Executive Summary
  • Disease Background
  • Methodology
  • Forecast
  • Bibliography
  • Appendix: Additional Sources

4 Marketed Drugs: Renal Cell Cancer

  • Executive Summary
  • Product Overview
  • Appendix

5 Product Profile

  • Afinitor
  • Avastin
  • Cabometyx
  • Inlyta
  • Lenvima
  • Nexavar
  • Opdivo
  • Sutent
  • Torisel
  • Votrient

6 Pipeline: Renal Cell Cancer

  • Executive Summary
  • Clinical Pipeline Overview
  • Recently Discontinued Drugs
  • Comparator Therapy
  • Clinical Trial Design
  • Appendix

7 Product Profile (Late Stage):

  • Keytruda
  • Tecentriq
  • Avelumab

For more information about this report visit https://www.researchandmarkets.com/research/j6vzsq/global_renal_cell?w=4

View Comments and Join the Discussion!